Timothy M. Lopez

Internal Medicine

445 Saint Michaels Dr
Santa Fe, NM 87505

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.

PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.

Journal: Cell reports. Medicine

Published: June 08, 2025

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.

Journal: Nature communications

Published: June 08, 2023

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.

Journal: Science translational medicine

Published: September 13, 2021

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.

Journal: Cancer research

Published: July 23, 2021

Showing 1-4 of 4

Last Updated: 09/26/2026